Sionna Therapeutics

Company snapshot

We are a life sciences company that is building on over a decade of extensive research on the genetic mutations associated with cystic fibrosis. We are developing first-in-class small molecules that are focused on a unique target with the potential to fully normalize CFTR function for the first time for the vast majority of people living with CF.

• 5 active pipeline program(s) linked via ClinicalTrials.gov.
• 5 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Sionna Therapeutics. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Sionna Therapeutics.

1. Jun 8, 2026 Clinical update

   pad-gauze with tranexamic acid (Hemostopan™) — Phase 3

2. Jun 8, 2026 Clinical update

   blood draw from three different vessels — Unknown

3. May 23, 2026 Clinical update

   Polyamide HD membrane — Phase 3

4. May 23, 2026 Clinical update

   SION-719 — Phase 2

5. May 23, 2026 Clinical update

   SION-451 — Phase 1

View all clinical trial activity →

• What is Sionna Therapeutics?

  Sionna Therapeutics is a pharma organization headquartered in Boston, USA. It trades on NYSE under ticker SION. Primary therapeutic focus areas include Cystic Fibrosis (CF), Accidental Hypothermia, Bleeding, End-stage Kidney Disease. NovaPharmaNews links 5 clinical program(s), 0

• Is Sionna Therapeutics publicly traded?

  Yes. Sionna Therapeutics is listed with ticker SION on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Sionna Therapeutics develop or market?

  We link 4 drug profile(s) where Sionna Therapeutics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/sionna-therapeutics#company-drugs.

• What are the latest developments for Sionna Therapeutics?

  In the last 12 months our linked public records show 5 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Sionna Therapeutics focus on?

  Sionna Therapeutics focuses on Cystic Fibrosis (CF), Accidental Hypothermia, Bleeding based on our analysis of their pipeline programs and drug development activities.